NCT04950842 is a Phase 1, PHASE2 clinical trial of JB-101 in Living-donor Liver Transplantation, sponsored by Juntendo University.

Who is sponsoring NCT04950842?

NCT04950842 is sponsored by Juntendo University.

What drugs are being tested in NCT04950842?

Interventions in NCT04950842: JB-101.

What condition does NCT04950842 study?

NCT04950842 studies Living-donor Liver Transplantation.

Is NCT04950842 still recruiting?

NCT04950842 is currently status unknown. Last updated 28 March 2024.

Last reviewed 2024-03-28 · How we verify

NCT04950842

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Induction of Transplant Tolerance in LDLT Via iTS

Status unknown Phase 1, PHASE2 Last updated 28 March 2024

What this trial tests

Phase 1, PHASE2 trial testing JB-101 in Living-donor Liver Transplantation in 10 participants. Status unknown.

Timeline

15 December 2020

Primary endpoint
28 February 2026

28 February 2026

Quick facts

Lead sponsor	Juntendo University
Phase	Phase 1, PHASE2
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	10
Start date	15 December 2020
Primary completion	28 February 2026
Estimated completion	28 February 2026
Sites	5 locations across Japan

Drugs / interventions tested

JB-101 — full drug profile →

Conditions studied

Living-donor Liver Transplantation — all drugs for Living-donor Liver Transplantation →

Sponsor

Juntendo University

Who can join

Adults 20 to 80, any sex, with Living-donor Liver Transplantation. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this clinical trial is to examine the immunotolerance-inducing ability (effectiveness) of induced inhibitory T cells JB-101 in patients with living-donor liver transplantation using "whether or not operational tolerance is achieved" as an index. And the safety of JB-101 will be evaluated.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Tolerance Induction Strategies in Organ Transplantation: Current Status and Future Perspectives.
Blein T, Ayas N, Charbonnier S, Gil A, et al · · 2025 · cited 2× · PMID 41127478 · DOI 10.3389/ti.2025.14958
Regulatory T cell therapy for xenotransplantation, what perspectives?
Porret R, Lana E, Mancarella A, Guillaume P, et al · · 2025 · cited 1× · PMID 41050672 · DOI 10.3389/fimmu.2025.1685682
Immunological Crossroads: Optimizing Antirejection Regimens to Sustain Antitumor Immunity in Liver Transplant Recipients with Hepatocellular Carcinoma.
Zhang C, Yuan X, Xie K. · · 2025 · PMID 41375072 · DOI 10.3390/cancers17233871

Verify or expand the search:

Other Juntendo University trials

Trials by the same sponsor.

NCT05392764 — Early Treatment With a Sodium-glucose Co-transporter 2 Inhibitor in High-risk Patients With Acute Heart Failure · Phase 3 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04950842 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Juntendo University
Last refreshed: 28 March 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04950842.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing